There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mereo Biopharma Group Plc (MREO – Research Report), GoodRx Holdings (GDRX – Research Report) and NewAmsterdam Pharma Company (NAMS – Research Report) with bullish sentiments.
Mereo Biopharma Group Plc (MREO)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Mereo Biopharma Group Plc on May 15 and set a price target of $6.00. The company’s shares closed last Friday at $3.20.
According to TipRanks.com, Schwartz is a 2-star analyst with an average return of
Mereo Biopharma Group Plc has an analyst consensus of Strong Buy, with a price target consensus of $6.25, a 91.1% upside from current levels. In a report issued on April 30, BTIG also maintained a Buy rating on the stock with a $6.00 price target.
See today’s best-performing stocks on TipRanks >>
GoodRx Holdings (GDRX)
In a report issued on May 15, Michael Cherny from Leerink Partners maintained a Buy rating on GoodRx Holdings, with a price target of $12.00. The company’s shares closed last Friday at $7.48.
According to TipRanks.com, Cherny is a 3-star analyst with an average return of
Currently, the analyst consensus on GoodRx Holdings is a Moderate Buy with an average price target of $9.43, a 17.0% upside from current levels. In a report issued on May 16, Raymond James also upgraded the stock to Buy with a $10.00 price target.
NewAmsterdam Pharma Company (NAMS)
Leerink Partners analyst Roanna Ruiz maintained a Buy rating on NewAmsterdam Pharma Company on May 17 and set a price target of $37.00. The company’s shares closed last Friday at $20.09.
According to TipRanks.com, Ruiz is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for NewAmsterdam Pharma Company with a $37.00 average price target, an 85.1% upside from current levels. In a report issued on May 8, RBC Capital also maintained a Buy rating on the stock with a $31.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MREO:
- Mereo BioPharma files to sell $175M of American Depositary Shares
- Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
- Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
